Capricor Therapeutics (CAPR) – Analysts’ Weekly Ratings Changes

Capricor Therapeutics (NASDAQ: CAPR) has recently received a number of price target changes and ratings updates:

• 3/13/2026 – Capricor Therapeutics was given a new $62.00 price target by Cantor Fitzgerald. They now have an “overweight” rating on the stock.
• 3/13/2026 – Capricor Therapeutics had its price target raised by B. Riley Financial, Inc. from $50.00 to $63.00. They now have a “buy” rating on the stock.
• 3/13/2026 – Capricor Therapeutics had its “overweight” rating reaffirmed by Piper Sandler. They now have a $58.00 price target on the stock, up from $45.00.
• 3/10/2026 – Capricor Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $60.00 price target on the stock.

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.